ISAL 2025 | An analysis of trends in overall survival in patients with AML

Yes, so what we did in that research project is we used SEER data from the US registry on cancers and cancer diseases and analyzed yearly hazard ratios to see trends in survival in AML. So what we did actually is we had a large cohort of 4 million cases and we filtered that for AML patients who got diagnosed after their childhood, so adult patients, and came up with around 35,000 cases that could be analyzed and that yielded enough statistical power to do yearly hazard ratios. So we got very detailed trends on survival over the last 40 plus years. And this showed that AML is a disease that can be tackled and that’s what this whole symposium shows, and we can see a continuous trend of improving survival. And interestingly, this is kind of constantly improving for younger patients and not for older patients. This started in the early 2000s. And the data does not tell us exactly why this is the case for the older patients, but there are some trends that are happening in parallel, like an increased percentage of patients who get transplanted with allogeneic stem cell transplantation. And since the 2000s, also in the older population, we see this continuous trend of improving survival rates. And this was kind of nice to see in the data that the research, improving treatment, improving care, shows effect and that we can see that also in this registry data from the US.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.